Wells Fargo Maintains Overweight on Elevance Health, Lowers Price Target to $593
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Stephen Baxter maintains an Overweight rating on Elevance Health (NYSE:ELV) but lowers the price target from $600 to $593.

July 22, 2024 | 1:48 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Wells Fargo analyst Stephen Baxter maintains an Overweight rating on Elevance Health but lowers the price target from $600 to $593.
The Overweight rating suggests a positive outlook, but the slight reduction in the price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100